Use of glatiramer acetate between 2010–2015: effectiveness, safety and reasons to start GA as first or second line treatment in Swiss multiple sclerosis patients

Abstract Background Glatiramer acetate (GA) is one of the first therapies approved for multiple sclerosis (MS). We prospectively included and monitored drug-naïve and pre-treated MS patients who had been prescribed GA for 1 year, to investigate reasons for GA prescription, its effectiveness and safe...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Chiara Zecca, Giulio Disanto, Rosaria Sacco, Gianna C. Riccitelli, Claudio Gobbi
Formato: Artigo
Lenguaje:Inglês
Publicado: BMC 2019-07-01
Colección:BMC Neurology
Materias:
CIS
GA
Glatiramer acetate
Multiple sclerosis
Relapsing remitting
Therapy
Acceso en línea:http://link.springer.com/article/10.1186/s12883-019-1383-6
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares